Introduction
Immunoglobulin A (IgA) nephropathy (IgAN), the most prevalent glomerular disease in the world and characterized by predominant IgA deposition in the mesangium, requires a renal biopsy for diagnosis. 1 It is initially regarded as a disease with a favorable prognosis but data from longterm follow-up studies have revealed that IgAN may progress to end-stage renal failure in up to 30% of patients with a follow up period of 20 years. 2, 3 There is a lack of a well-documented diagnostic approach for IgAN risk; and reliable biomarkers are needed for the non-invasive diagnosis of this disease and to more fully delineate its natural history and risk for progression. Current evidence indicates that gene polymorphism of some genes is associated with the susceptibility of IgAN. [4] [5] [6] Aldosterone, one of the main effectors of the renin-angiotensin system, has classically been thought to act as a regulator for the absorption of sodium and water, as well as the excretion of potassium in normal physiology, and as a mediator of edema in numerous disease states. 7 Aldosterone secretion is regulated largely by the expression level of the final enzyme required for its biosynthesis, aldosterone synthase (CYP11B2). Expression of CYP11B2 is regulated by angiotensin II through cyclic adenosine monophosphate (cAMP) dependent modulation of the gene promoter region, which contains a variety of control factors. 7 Therefore, genetic variants in CYP11B2, which may be associated with the biosynthesis of aldosterone in local tissue, may also affect the progression of renal dysfunction in primary glomerulonephritis. Aldosterone, via its binding to and activation of the mineralocorticoid receptors, is a main regulator of blood pressure by controlling renal sodium reabsorption. 8 Gene polymorphism is one of the most important factors taking part in the etiology of some diseases. The evidence from meta-analysis might be powerful compared with the individual investigation. There was no meta-analysis to evaluate the association of the CYP11B2-344C/T gene polymorphism with the risk of IgAN and progression of IgAN. This meta-analysis was conducted to investigate whether the CYP11B2-344C/T gene polymorphism was associated with the risk of IgAN and the progression of IgAN, by widely collecting reported studies.
Materials and methods

Search strategy
The relevant studies were sought from the electronic databases of PubMed and the Cochrane Library on 1 October 2013. The retrieval strategy of '(IgA nephropathy OR IgA renal disease OR IgAN) AND (aldosterone synthase OR CYP11B2) AND (polymorphism OR variant)' was entered into these databases. Additional reports were identified through references cited in recruited articles.
Inclusion and exclusion criteria
Inclusion criteria: (a) The outcome had to be IgAN; (b) there had to be at least two comparison groups (case group vs control group); (c) investigation should provide data on CYP11B2 genotype distribution.
Exclusion criteria: (a) Review articles and editorials; (b) case reports; (c) preliminary result not on CYP11B2-344C/T gene polymorphism or outcome; (d) investigating the role CYP11B2 gene expression in disease; (e) if multiple publications for the same data from the same study group occurred, we only recruited the later paper into our final analysis.
Data extraction and synthesis
The following information from each eligible study was extracted independently by two investigators: first author's surname, year of publication, ethnicity, genotyping methods, control source of the control group, and the number of cases and controls for CYP11B2-344C/T genotypes. The results were compared and disagreement was resolved by discussion.
Statistical analysis
Cochrane Review Manager Version 5 (Cochrane Library, UK) was used to calculate the available data from each study. The pooled statistic was counted using the fixed effects model, but a random effects model was conducted when the p value of heterogeneity test was less than 0.1. [9] [10] [11] Results were expressed with odds ratios (ORs) for dichotomous data, and 95% confidence intervals (CIs) were also calculated. 12, 13 The value of p<0.05 was required for the pooled OR to be statistically significant. 14 I 2 was used to test the heterogeneity among the included studies. Sensitivity analysis was also performed according to source of the controls (healthy vs hospital) and sample size of case (<100 vs ≥100).
Results
Study characteristics
Four studies [15] [16] [17] [18] reporting the relationship between CYP11B2-344C/T gene polymorphism and IgAN susceptibility/IgAN progression were included into this metaanalysis. Four investigations [15] [16] [17] [18] were conducted for the association of CYP11B2-344C/T gene polymorphism and IgAN risk, and two studies 15, 16 were performed for the relationship between CYP11B2-344C/T gene polymorphism and IgAN progression ( Table 1) . Those four investigations contained 542 IgAN patients and 707 controls. The average distribution frequency of C allele of CYP11B2-344C/T in the IgAN group was 32.57% and the average frequency in the control group was 39%. The average distribution frequency of the case group for C allele was lower than that in the control group (case/ control=0.84). Figure 1 for overall populations, Table 2 ).
Association of CYP11B2-344C/T gene polymorphism with IgAN progression
In this meta-analysis, all the included studies were from the Asian population, and CYP11B2-344C/T gene polymorphism was not associated with IgAN progression in overall populations and Asians (overall populations: Figure 2 and Table 2 ).
Sensitivity analysis
Sensitivity analysis for the relationship between CYP11B2 -344C/T gene polymorphism and IgAN risk was also performed according to according to the source of the controls (healthy vs hospital). The controls of all the included studies for CYP11B2-344C/T were from healthy sources, and the results were the same as in the non-sensitivity analysis. Sensitivity analysis for the relationship between CYP11B2-344C/T gene polymorphism and IgAN risk was also performed according to sample size of case (<100 vs ≥100). We found that the results were also similar to the non-sensitivity analysis, but the CYP11B2-344C/T gene polymorphism was not associated with IgAN risk in the sensitivity analysis according to sample size of less than 100 (data not shown).
discussion
Gene polymorphism, one of the most important factors, takes part in the etiology of IgAN disease. There were some interesting studies performed to assess the association of the polymorphism of some genes with IgAN risk or IgAN progression. Zhou et al. 2 performed a meta-analysis to evaluate the association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and end-stage renal disease (ESRD) susceptibility in IgAN patients, and reported that the DD homozygote was a significant genetic molecular marker for the onset of ESRD in IgAN patients. Qin et al. 3 performed a meta-analysis to evaluate the association of ACE gene polymorphism with IgAN in different ethnic groups, and showed that the D allele or DD genotype was associated with IgAN risk in the Asian population, but not in the Caucasian population; there was no significant association between the D allele or DD gene and IgAN progression for Asians and Caucasians. In this meta-analysis, we also performed a meta-analysis to assess the association of CYP11B2-344C/T gene polymorphism and IgAN risk or IgAN progression.
In this study, the average distribution frequency of CYP11B2-344C/T C allele in the IgAN group was 0.84fold increased when compared with that in control group. The average distribution frequency data indicated that the CYP11B2-344C/T C allele in IgAN group was lower when compared with that in control group. However, there were only three studies for this calculation, and this result might be less robust.
There was no meta-analysis performed to investigate the association of CYP11B2-344C/T gene polymorphism and the risk of IgAN in the past. This study was conducted firstly to assess the relationship between CYP11B2-344C/T gene polymorphism and the risk of IgAN and the progression of IgAN.
Four studies were included in this meta-analysis. We found that most of them reported that CYP11B2-344C/T gene polymorphism was not associated with the risk of IgAN. Kim et al. 15 included a total of 238 IgAN and 300 healthy cohorts in their study, and showed that the genotype distributions of the polymorphisms were similar between patients and controls, and the individual genotypes taken alone were not associated with the progression of renal dysfunction. Huang et al. 16 included 130 Chinese patients with IgAN and 120 healthy Chinese subjects, and reported that the CYP11B2-344C/T genotype distributions were similar in patients with IgAN and in controls, and the CYP11B2-344C/T gene polymorphism was not associated with ESRD progression in IgAN-ESRD patients. Bantis et al. 17 conducted a study in 143 patients with biopsyproven IgAN and 100 healthy controls, and indicated that aldosterone synthase gene C-344T polymorphism was a risk factor for accelerated progression in Caucasian patients with IgAN. Pawlik et al. 18 included 31 IgAN patients and 187 controls, and reported that the CYP11B2-344C/T gene polymorphism might be an independent risk factor for IgAN. These two studies from the Caucasian population might get a more positive result than in the Asian population.
Our meta-analysis indicated that the CYP11B2-344C/T gene polymorphism was not associated with IgAN risk for overall populations and Asians in this meta-analysis. Interestingly, the C allele and CC genotype were associated with the risk of IgAN in Caucasians, but the TT genotype not. The outcome might be robust to some extent. However, those findings should be regarded cautiously because many other ingredients, such as small sample size of the included report, limited statistical power, heterogeneity of enrolled cases, variable study designs and different interventions, were closely related to affect the results. Since the number of included studies is rather small, more studies should be performed to evaluate the relationship in the future.
In conclusion, the results in our study support that CYP11B2-344C/T gene polymorphism was not associated with IgAN risk for overall populations and Asians in this meta-analysis. Interestingly, C allele and CC genotype were associated with the risk of IgAN in Caucasians, but not the TT genotype. However, more association investigations are required to further clarify the role of the CYP11B2-344C/T gene polymorphism in predicting the risk of IgAN and the progression of IgAN.
declaration of conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
